The multicenter prospective randomized controlled trial included 197 patients who received one- or two-level instrumented posterolateral lumbar fusion at one of eight participating institutions. The researchers followed patients for two to four years postoperatively and found:
• No significant adverse events attributed to the study drug when compared with controls.
• The control group experienced significantly more graft-site complications than one may expect.
• The two groups had similar 36-Item Short Form Health Survey, Oswestry Disability Index and leg/back pain scores.
• Around 94 percent of the patients who received rhBMP-2 reported radiographical fusion rates, compared with 69 percent of the patients who received autograft.
As a result of their findings, the researchers suggest that “use of rhBMP-2 should be considered in cases where lumbar arthrodesis is of primary concern.”
More Articles on Spine Surgery:
19 Spine Devices Receive FDA 510(k) Clearance in November
A New Generation of Spine Surgeons: How Minimally Invasive Techniques Impact Training
Cervical Spinal Fusion for Trauma: 5 Outcomes & Cost Differences for Weekend Admits
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
